Bayer Sues Lupin Over Generic Cipro

By Richard Vanderford

Law360, New York (February 19, 2010, 1:23 PM ET) -- Bayer Schering Pharma AG has hit Indian drugmaker Lupin Ltd. with a patent infringement suit over plans to introduce generic versions of Cipro, the branded form of anti-microbial drug ciprofloxacin.

Bayer filed suit against Lupin and its U.S. subsidiary on Thursday in the U.S. District Court for the District of Maryland, in response to several abbreviated new drug applications Lupin has filed with the U.S. Food and Drug Administration.

Lupin's planned drugs — 250mg/5mL and 500mg/5mL versions of Cipro oral suspension — infringe Bayer-held U.S. Patent...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles